Neoplasm Invasiveness

The grounding does not support a specific causal aetiology for neoplasm invasiveness itself. It indicates that invasive behavior is associated with intrinsic alterations in tumor cells and, in some cancers, with malignant progression.

Invasiveness is linked to tumor cell movement, proliferation, and changes in gene expression that support infiltration of surrounding tissue. The tumor microenvironment contributes through cross-talk with stromal and immune cells, including cytokine signaling, and matrix metalloproteinases help remodel extracellular matrix barriers that normally restrain cell migration. Apoptosis-related changes and immune evasion within the tumor microenvironment are also implicated in progression and spread.

The grounding does not support general risk factors for neoplasm invasiveness as a standalone entity. In the bladder cancer review, advanced age, male sex, and cigarette smoking are described as contributing to bladder cancer development, but not specifically to invasiveness across neoplasms.

The grounding does not support a general standard of care for neoplasm invasiveness as a standalone entity. For non-muscle-invasive bladder tumors, the review describes endoscopic resection with adjuvant intravesical therapy, and the co-studied agents include intravesical BCG vaccine and chemotherapy drugs such as cisplatin and gemcitabine; the immunotherapy literature also mentions checkpoint blockade approaches such as nivolumab in the context of tumor progression.